Supernus Pharmaceuticals Inc. (SUPN), Tuesday announced a licensing deal with M8 Pharmaceuticals to commercialize its ADHD drug Qelbree under the latter's trademark in Latin America.FDA-approved Qelbree is a prescription medicine to treat attention deficit hyperactivity disorder in adults and children of 6 years of age and older.

Supernus Pharmaceuticals Inc.（SUPN）周二宣布与M8 Pharmaceuticals达成许可协议，将其ADHD药物Qelbree在拉丁美洲以后者的商标进行商业化。FDA批准的Qelbree是一种治疗成人和6岁及以上儿童注意力缺陷多动障碍的处方药。

The company also announced that a second phase 4 clinical trial in pre-school-age children with ADHD is expected to begin in January 2024.Currently, Supernus's stock is trading at $30.82, up 1.31 percent on the Nasdaq. For comments and feedback contact: editorial@rttnews.comBusiness News.

该公司还宣布，针对学龄前多动症儿童的第二阶段4临床试验预计将于2024年1月开始。目前，Supernus的股价为30.82美元，在纳斯达克上涨1.31%。如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻。

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision in March 2024

2024年3月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In November 2023

2023年11月美国食品和药物管理局（FDA）决定生物技术股